An Evaluation of the Potential for VH4011499 Drug-drug-interactions
A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants
The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
研究联系人备份
- 姓名:EU GSK Clinical Trials Call Center
- 电话号码:+44 (0) 20 89904466
- 邮箱:GSKClinicalSupportHD@gsk.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).
-
Male or female:
-
Male Participants:
No restrictions for male participants.
-
A female participant (female sex assigned at birth) is eligible to participate if:
-
They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
- Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Capable of giving signed informed consent.
Exclusion Criteria:
- History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
- Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
- A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
- Clinically significant abnormal blood pressure at Screening.
- Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
- Breast cancer within the past 10 years.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
- History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
- History of seizure(s) and / or other clinically significant neurological conditions.
- Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
- Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
- Participant is mentally or legally incapacitated.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
- Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
- Unable to refrain from the use of prescription or non-prescription medications.
- Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
- Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
- Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
- Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
- Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
- Current enrollment or past participation in this clinical study.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
- Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
- Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
- Positive Hepatitis C antibody test result at Screening.
- Positive pre-study drug/alcohol screen.
- Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
- Regular alcohol consumption within 6 months prior to Screening.
- Regular use of known drugs of abuse.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
- Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
- Prior exposure to VH4011499 or Lenacapavir in any formulation..
- Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
- Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort 1: VH4011499 + Ritonavir
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir. |
VH4011499 is administered to the participants based on the protocol schedule. Ritonavir is administered to the participants based on the protocol schedule. |
|
实验性的:Cohort 2: VH4011499 + Efavirenz
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz. |
VH4011499 is administered to the participants based on the protocol schedule. Efavirenz is administered to the participants based on the protocol schedule. |
|
实验性的:Cohort 3: VH4011499 + Carbamazepine
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose. |
VH4011499 is administered to the participants based on the protocol schedule. Carbamazepine is administered to the participants based on the protocol schedule. |
|
实验性的:Cohort 4: VH4011499 + Metformin + Digoxin
Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Metformin is administered to the participants based on the protocol schedule. Digoxin is administered to the participants based on the protocol schedule. |
|
实验性的:Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin
Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Rosuvastatin is administered to the participants based on the protocol schedule. Pitavastatin is administered to the participants based on the protocol schedule. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
Cmax of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
|
Day 26
|
|
Cmax of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
|
Day 37
|
|
Cmax of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-t) of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
|
Day 26
|
|
AUC(0-t) of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
|
Day 37
|
|
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
|
Day 26
|
|
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
|
Day 37
|
|
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
|
Day 41
|
|
Cmax of Metformin when administered alone
大体时间:Day 1
|
Day 1
|
|
Cmax of Metformin when co-administered with VH4011499
大体时间:Day 16
|
Day 16
|
|
AUC(0-t) of Metformin when administered alone
大体时间:Day 1
|
Day 1
|
|
AUC(0-t) of Metformin when co-administered with VH4011499
大体时间:Day 16
|
Day 16
|
|
AUC(0-inf) of Metformin when administered alone
大体时间:Day 1
|
Day 1
|
|
AUC(0-inf) of Metformin when co-administered with VH4011499
大体时间:Day 16
|
Day 16
|
|
Cmax of Digoxin when administered alone
大体时间:Day 1
|
Day 1
|
|
Cmax of Digoxin when co-administered with VH4011499
大体时间:Day 16
|
Day 16
|
|
AUC(0-t) of Digoxin when administered alone
大体时间:Day 1
|
Day 1
|
|
AUC(0-t) of Digoxin when co-administered with VH4011499
大体时间:Day 16
|
Day 16
|
|
AUC(0-inf) of Digoxin when administered alone
大体时间:Day 1
|
Day 1
|
|
AUC(0-inf) of Digoxin when co-administered with VH4011499
大体时间:Day 16
|
Day 16
|
|
Cmax of Rosuvastatin when administered alone
大体时间:Day 5
|
Day 5
|
|
Cmax of Rosuvastatin when co-administered with VH4011499
大体时间:Day 22
|
Day 22
|
|
AUC(0-t) of Rosuvastatin when administered alone
大体时间:Day 5
|
Day 5
|
|
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
大体时间:Day 22
|
Day 22
|
|
AUC(0-inf) of Rosuvastatin when administered alone
大体时间:Day 5
|
Day 5
|
|
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
大体时间:Day 22
|
Day 22
|
|
Cmax of Pitavastatin when administered alone
大体时间:Day 1
|
Day 1
|
|
Cmax of Pitavastatin when co-administered with VH4011499
大体时间:Day 17
|
Day 17
|
|
AUC(0-t) of Pitavastatin when administered alone
大体时间:Day 1
|
Day 1
|
|
AUC(0-t) of Pitavastatin when co-administered with VH4011499
大体时间:Day 17
|
Day 17
|
|
AUC(0-inf) of Pitavastatin when administered alone
大体时间:Day 1
|
Day 1
|
|
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
大体时间:Day 17
|
Day 17
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with adverse events (AEs), overall and by grade.
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Number of participants with AEs leading to study treatment discontinuation
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
大体时间:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
大体时间:Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
Tmax of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
|
Day 26
|
|
|
Tmax of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
|
Day 37
|
|
|
Tmax of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
|
Day 41
|
|
|
Apparent oral clearance (CL/F) of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
CL/F of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
|
Day 26
|
|
|
CL/F of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
|
Day 37
|
|
|
CL/F of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
|
Day 41
|
|
|
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
大体时间:Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
t1/2 of VH4011499 when co-administered with Ritonavir
大体时间:Day 26
|
Day 26
|
|
|
t1/2 of VH4011499 when co-administered with Efavirenz
大体时间:Day 37
|
Day 37
|
|
|
t1/2 of VH4011499 when co-administered with Carbamazepine
大体时间:Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Metformin and Digoxin
大体时间:Day 16
|
Day 16
|
|
|
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
大体时间:Day 16
|
Day 16
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
大体时间:Day 16
|
Day 16
|
|
|
Cmax of Ritonavir when co-administered with VH4011499
大体时间:Day 26
|
Day 26
|
|
|
AUC(0-t) of Ritonavir when co-administered with VH4011499
大体时间:Day 26
|
Day 26
|
|
|
AUC(0-inf) of Ritonavir when co-administered with VH4011499
大体时间:Day 26
|
Day 26
|
|
|
Cmax of Efavirenz when co-administered with VH4011499
大体时间:Day 37
|
Day 37
|
|
|
AUC(0-t) of Efavirenz when co-administered with VH4011499
大体时间:Day 37
|
Day 37
|
|
|
AUC(0-inf) of Efavirenz when co-administered with VH4011499
大体时间:Day 37
|
Day 37
|
|
|
Cmax of Carbamazepine when co-administered with VH4011499
大体时间:Day 41
|
Day 41
|
|
|
AUC(0-t) of Carbamazepine when co-administered with VH4011499
大体时间:Day 41
|
Day 41
|
|
|
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
大体时间:Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Rosuvastatin
大体时间:Day 22
|
Day 22
|
|
|
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
大体时间:Day 22
|
Day 22
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
大体时间:Day 22
|
Day 22
|
|
|
Cmax of VH4011499 when co-administered with Pitavastatin
大体时间:Day 17
|
Day 17
|
|
|
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
大体时间:Day 17
|
Day 17
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
大体时间:Day 17
|
Day 17
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 血源性感染
- 泌尿生殖系统疾病
- 生殖器疾病
- 免疫系统疾病
- 感染
- RNA 病毒感染
- 病毒病
- 传染病
- 性传播疾病,病毒
- 性病
- 慢病毒感染
- 逆转录病毒科感染
- 免疫缺陷综合症
- 慢病毒病
- 艾滋病毒感染
- 获得性免疫缺陷综合症
- 硫化合物
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,融合环
- 噻唑
- Azoles
- 碳氢化合物
- 碳水化合物
- 多环化合物
- 糖苷
- 酰胺
- 嘧啶
- 类固醇
- 融合环化合物
- 碳氢化合物,卤素
- Biguanides
- 鸟齿
- 胺
- 磺酰胺
- 硫酮
- Dibenzazepines
- 杂环化合物,三环
- 氟苯烯
- 碳氢化合物,氟
- Digitalis糖苷
- 心脏甲苯酚
- 心脏糖苷
- Cardanolides
- 瑞舒伐他汀钙
- 地高辛
- 二甲双胍
- 利托那韦
- 卡马西平
- Efavirenz
- pitavastatin
其他研究编号
- 309014
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.